PROMUS Element™ Plus H7493911432220Recalls & reported problems
Boston Scientific Corporation · Everolimus-Eluting Platinum Chromium Coronary Stent System · Class 3 · Implant
All models of PROMUS Element Plus (44)
Data updated Oct 16, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 1
- Deaths reported
- 0
- Injuries reported
- 1
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 08714729807803), received between Mar 29, 2018 and Mar 29, 2018 — classified as 1 injury.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem1
Patient problems
- Obstruction/Occlusion1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
InjuryMar 29, 2018Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
(B)(4) CLINICAL STUDY. IT WAS REPORTED THAT JAILING OCCURRED. IN (B)(6) 2013, THE PATIENT WAS REFERRED FOR EMERGENT CARDIAC CATHETERIZATION. SUBSEQUENTLY, THE INDEX PROCEDURE WAS PERFORMED. TARGET LESION #1 WAS A DE NOVO LESION LOCATED IN THE THIRD OBTUSE MARGINAL BRANCH (OM3) WITH 95% STENOSIS AND WAS 30MM LONG WITH A REFERENCE VESSEL DIAMETER OF 2.25MM. TARGET LESION #1 WAS TREATED WITH PRE-DILATATION AND PLACEMENT OF A 2.50X32MM PROMUS ELEMENT¿ PLUS STENT. FOLLOWING POST DILATATION, RESIDUAL STENOSIS WAS 0%. AFTER DEPLOYMENT OF STUDY STENT IN OM3, JAILING WAS OBSERVED IN OM2 EXTENDING UP THROUGH MID LEFT CIRCUMFLEX ARTERY. IT WAS REPORTED THAT OM2 WAS JAILED APPROXIMATELY WITH 50% OSTIAL STENOSIS. GIVEN THE COMPLEXITY OF THE PROCEDURE AND THE RESTORATION OF TIMI 3 FLOW POST THE PROCEDURE, NO INTERVENTION WAS PERFORMED IN RESPONSE TO JAILING. TARGET LESION #2 WAS A DE NOVO LONG LESION LOCATED FROM PROXIMAL LEFT CIRCUMFLEX ARTERY (LCX) TO DISTAL LCX WITH 100% STENOSIS AND WAS 26MM LONG WITH A REFERENCE VESSEL DIAMETER OF 2.00MM. TARGET LESION #2 WAS TREATED WITH DIRECT PLACEMENT OF A 2.25X28MM PROMUS ELEMENT¿ PLUS STENT WITH 0% RESIDUAL STENOSIS. TARGET LESION #3 WAS A DE NOVO LON
Patient problems: Obstruction/Occlusion
MAUDE report 7382946 ↗
Other Coronary drug-eluting stent devices
- SYNERGY™ H7493926038300Boston Scientific Corporation · Coronary drug-eluting stent8 deaths124 reports
- SYNERGY™ H7493926016300Boston Scientific Corporation · Coronary drug-eluting stent7 deaths106 reports
- SYNERGY™ H7493926020300Boston Scientific Corporation · Coronary drug-eluting stent9 deaths90 reports
- XIENCE Sierra™ 1550350-33Abbott Vascular Inc. · Coronary drug-eluting stent1 recall32 reports
- SYNERGY™ H7493926016250Boston Scientific Corporation · Coronary drug-eluting stent6 deaths82 reports
- Resolute Onyx™ RONYX30022UXMedtronic, Inc. · Coronary drug-eluting stent6 deaths76 reports
- SYNERGY™ H7493926024300Boston Scientific Corporation · Coronary drug-eluting stent3 deaths75 reports
- Resolute Onyx™ RONYX30015UXMedtronic, Inc. · Coronary drug-eluting stent3 deaths73 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 16, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page